Education
About Us
Working with TipRanks
Follow Us
James Frates Insider Profile
11 Followers
James Frates, SVP, Alks Inc; CFO ALKS at Alkermes, holds 317.52K shares in Amylyx Pharmaceuticals Inc (Ticker: AMLX), holds 2.85K shares in SAGE Therapeutics (Ticker: SAGE), holds 247.50K shares in Alkermes (Ticker: ALKS). Most recently, James Frates Sold ― shares of Amylyx Pharmaceuticals Inc on Apr 02, 2025 for an estimated value of 37.70K.
Profitable Transactions
4 out of 6 Profitable Transactions
Average Return
+37.70%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that James Frates holds in companies
Most Profitable Insider Trade
The most profitable trade made by James Frates
James Frates's Trading History
Alkermes
May 14, 2020
SVP, Alks Inc; CFO ALKS
Uninformative Buy
258.08K
$6.57M
Amylyx Pharmaceuticals Inc
Apr 02, 2025
CFO
Informative Sell
37.70K
$2.64M
SAGE Therapeutics
Jun 17, 2021
Director
Informative Buy
99.73K
$24.92K
List of latest transactions for each holding click on a transaction to see James Frates's performance on stock
You May Also Like
James Frates insider profile FAQ
What is the percentage of profitable transactions made by James Frates?
The percentage of profitable transactions made by James Frates is 67%.
What is the average return per transaction made by James Frates?
The average return per transaction made by James Frates is 37.70%.
What stocks does James Frates hold?
James Frates holds: ALKS, AMLX, SAGE stocks.
What was James Frates’s latest transaction?
James Frates latest transaction was an Informative Sell of $37.70K.
What was James Frates's most profitable transaction?
James Frates’s most profitable transaction was an Informative Buy of SAGE stock on July 23, 2014. The return on the trade was 173.30%.
What is James Frates's role in Alkermes?
James Frates's role in Alkermes is SVP, Alks Inc; CFO ALKS.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.